ATLANTA, Jan. 23, 2013 (GLOBE NEWSWIRE) -- OTC Stock Review has published an updated report on PositiveID Corporation (OTCBB:PSID). Our previous reports issued in June and September 2012 resulted in profitable trades for our subscribers. We are bullish on PSID, since the Company announced on December 20th that it had entered into a license and teaming agreement with The Boeing Company, which includes a license fee payment to PSID of $2.5 million.
PSID's M-BAND focuses on airborne bio-threat detection by continuously analyzing air samples for the detection of bacteria, viruses, and toxins. Results are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments in the aggregate. M-Band BAND was developed under contract for the Department of Homeland Security and was featured in a Businessweek article last summer.
The initial roll-out of the M-BAND system is expected to occur in mid to late 2013 and span over five years with an estimated value of over three billion dollars. With the roll-out slated for mid-2013, we believe there could be additional positive news on the horizon for PSID.
NOTE: The purpose of this release is to introduce the reader to OTCStockReview.com and PositiveID Corp. OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. Information and opinions presented in this release are solely for informative purposes and not intended, nor should they be construed as, investment advice. This document contains information obtained from public sources about PositiveID Corp., but does not contain all the relevant material information necessary to evaluate the company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of PositiveID Corp., as profiled. OTC Stock Review has been compensated two thousand five hundred dollars to perform investor relations services for PositiveID Corp. Officers, directors, and employees of OTC Stock Review, may hold an equity position in a profiled Company and may trade in these securities for their own accounts. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled companies. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm
OTC Stock Review David Kugelman 404-281-8556